Newsfeeds Archive - Page 19071 of 19074

2 minute read

3M to Sell Rights to Neoplast and Neobun Brands and Related Assets in Thailand and Certain other Southeast Asia Countries; Terms Not Disclosed

July 1, 4:59 AM

3M (NYSE: MMM) has entered into an agreement to sell its rights to the Neoplast™ and Neobun™ brands and related assets in Thailand and certain other Southeast Asia countries, including the manufacturing assets of its Ladlumkaew, Thailand, facility to Selic Corp Public Company Limited (Selic), a company focusing on bon

MMM

1 minute read

Credit Suisse Upgrades Coupang to Outperform, Lowers Price Target to $19

By Benzinga Newsdesk

July 1, 4:57 AM

Credit Suisse analyst Soyun Shin upgrades Coupang (NYSE:CPNG) from Neutral to Outperform and lowers the price target from $28 to $19.

CPNG

1 minute read

DA Davidson Initiates Coverage On Harley-Davidson with Neutral Rating, Announces Price Target of $35

By Benzinga Newsdesk

July 1, 4:54 AM

DA Davidson analyst Brandon Rolle initiates coverage on Harley-Davidson (NYSE:HOG) with a Neutral rating and announces Price Target of $35.

HOG

5 minute read

Akerna Shares Dip 53%, Here’s 78 Biggest Movers From Yesterday

By Lisa Levin

July 1, 4:52 AM

Gainers Revelation Biosciences, Inc. (NASDAQ: REVB) surged 77.4% to close at $1.11 on Thursday after jumping 27% on Wednesday. Revelation Biosciences recently announced completion of dosing for Phase 1b CLEAR clinical study of REVTx-99b for the treatment of allergic rhinitis.

ADSE

1 minute read

B of A Securities Downgrades Duck Creek Technologies to Neutral, Announces $16 Price Target

By Benzinga Newsdesk

July 1, 4:51 AM

B of A Securities analyst Brad Sills downgrades Duck Creek Technologies (NASDAQ:DCT) from Buy to Neutral and announces $16 price target.

DCT

2 minute read

Oxford Biomedica Signed New Three year Agreement with AstraZeneca

By Charles Gross

July 1, 4:49 AM

Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the Company"), a leading gene and cell therapy group, today announces that it has signed a new three year Master Services & Development Agreement ("the Agreement") with AstraZeneca UK Ltd ("AstraZeneca") which would facilitate potential future manufacturing opportunities for the AstraZeneca COVID-19 vaccine.

AZN